162 related articles for article (PubMed ID: 33468793)
1. [A Case of Chemotherapy with Low-Dose Paclitaxel and Bevacizumab for Elderly Recurrent Breast Cancer Patient].
Munemoto M; Kano S; Ishikawa S; Makita N; Yagi Y; Oonishi I; Kayahara M
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2038-2040. PubMed ID: 33468793
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report.
Ishizuna K; Ninomiya J; Kojima M; Kawashima M; Nozaki M; Yamagishi H; Ueda Y; Oya M
BMC Res Notes; 2013 Jul; 6():254. PubMed ID: 23830415
[TBL] [Abstract][Full Text] [Related]
3. [A Case of Recurrent Breast Cancer with Carcinomatous Pleurisy Successfully Treated with Biweekly Paclitaxel and Bevacizumab].
Yoshida T; Goto Y; Sakiyama K; Kimura M
Gan To Kagaku Ryoho; 2016 Nov; 43(11):1397-1400. PubMed ID: 27899783
[TBL] [Abstract][Full Text] [Related]
4. [Axillary Arterial Bleeding with Administration of Bevacizumab plus Paclitaxel in a Patient with Recurrent Breast Cancer-A Case Report].
Tsuruda Y; Masuda T; Hayashi N; Noda M; Otsu H; Kuroda Y; Eguchi H; Tanaka F; Natsugoe S; Mimori K
Gan To Kagaku Ryoho; 2020 Jan; 47(1):117-119. PubMed ID: 32381877
[TBL] [Abstract][Full Text] [Related]
5. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
6. [A Case of Locally Advanced and Metastatic Breast Cancer Treated with Preoperative Bevacizumab Combination Chemotherapy That Attained Local Control].
Watanabe N; Furukawa J; Minoji T; Tamai K; Kitahara T; Yamamura N; Okamura S; Fukuchi N; Ebisui C; Yokouchi H; Kinuta M
Gan To Kagaku Ryoho; 2018 Jul; 45(7):1097-1099. PubMed ID: 30042280
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
[TBL] [Abstract][Full Text] [Related]
8. [Paclitaxel plus Bevacizumab Therapy plus Surgical Resection Results in Local Control of Stage ⅢC Breast Cancer].
Tanaka M; Ono S; Nohara Y; Yoshinaga Y; Sato T; Yamashita S; Morita A; Takagi S
Gan To Kagaku Ryoho; 2021 Nov; 48(11):1393-1395. PubMed ID: 34795133
[TBL] [Abstract][Full Text] [Related]
9. [A Case of Recurrent Breast Cancer with Carcinomatous Pleurisy Successfully Treated with Paclitaxel and Bevacizumab after Radical Mastectomy].
Sakaguchi N; Moriya T; Yamazaki T; Yamagishi Y; Hasegawa S; Tsuda H; Hase K; Yamamoto J
Gan To Kagaku Ryoho; 2015 Jun; 42(6):751-3. PubMed ID: 26199251
[TBL] [Abstract][Full Text] [Related]
10. [Recurrence of skin and lymph nodes from asynchronous breast cancer successfully treated with paclitaxel and toremifene therapy--a case report].
Sakurai K; Enomoto K; Tani M; Kitajima A; Amano S; Shiono M
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2222-4. PubMed ID: 19106577
[TBL] [Abstract][Full Text] [Related]
11. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
Smith IE; Pierga JY; Biganzoli L; Cortés-Funes H; Thomssen C; Pivot X; Fabi A; Xu B; Stroyakovskiy D; Franke FA; Kaufman B; Mainwaring P; Pienkowski T; De Valk B; Kwong A; González-Trujillo JL; Koza I; Petrakova K; Pereira D; Pritchard KI;
Ann Oncol; 2011 Mar; 22(3):595-602. PubMed ID: 20819780
[TBL] [Abstract][Full Text] [Related]
12. [Combination Therapy of Bevacizumab plus Paclitaxel Was Effective for a Metastatic Choroidal Tumor Secondary to Breast Cancer in a Patient with Ocular Symptoms].
Hattori M; Shirahane K; Sakai M; Sassa Y; Nishihara Y; Aibe H; Masuda M; Mori D
Gan To Kagaku Ryoho; 2020 Aug; 47(8):1221-1224. PubMed ID: 32829359
[TBL] [Abstract][Full Text] [Related]
13. [A Case of Pseudopancreatic Cyst Development during Bevacizumab plus Paclitaxel Therapy for Pancreatic Metastasis of Breast Cancer].
Shiina N; Fujisaki K; Miyoshi T; Yokomizo J; Sai G; Wakabayashi Y; Ootsubo Y
Gan To Kagaku Ryoho; 2021 Aug; 48(8):1061-1063. PubMed ID: 34404077
[TBL] [Abstract][Full Text] [Related]
14. [A Case of Triple Negative Breast Cancer with Left Buttock Metastasis].
Abe A; Nishimura A; Okano K; Suzuki T; Hakamada K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1624-1626. PubMed ID: 38303362
[TBL] [Abstract][Full Text] [Related]
15. [A Case of Male Recurrent Breast Cancer Successfully Treated with Bevacizumab plus Paclitaxel Therapy for Carcinomatous Pericarditis].
Nara M; Oshino T; Hagio K; Takazaki E; Yamashita H
Gan To Kagaku Ryoho; 2020 Jul; 47(7):1085-1087. PubMed ID: 32668857
[TBL] [Abstract][Full Text] [Related]
16. [A case of recurrent breast cancer with carcinomatous pleurisy responding to bevacizumab and paclitaxel therapy].
Sato Y; Nakagawa T; Sato T; Nagahara M; Sugihara K
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2387-9. PubMed ID: 24394121
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
18. [Patient with Recurrent Breast Cancer Who Developed Radiation Esophagitis with Severe Esophageal Stenosis after Combined Bevacizumab and Paclitaxel Therapy-A Case Report].
Matsuura K; Osaki A; Ichinose Y; Fujimoto A; Nukui A; Saeki T
Gan To Kagaku Ryoho; 2020 Nov; 47(11):1605-1608. PubMed ID: 33268737
[TBL] [Abstract][Full Text] [Related]
19. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Martin M; Roche H; Pinter T; Crown J; Kennedy MJ; Provencher L; Priou F; Eiermann W; Adrover E; Lang I; Ramos M; Latreille J; Jagiełło-Gruszfeld A; Pienkowski T; Alba E; Snyder R; Almel S; Rolski J; Munoz M; Moroose R; Hurvitz S; Baños A; Adewoye H; Hei YJ; Lindsay MA; Rupin M; Cabaribere D; Lemmerick Y; Mackey JR;
Lancet Oncol; 2011 Apr; 12(4):369-76. PubMed ID: 21429799
[TBL] [Abstract][Full Text] [Related]
20. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).
Rugo HS; Barry WT; Moreno-Aspitia A; Lyss AP; Cirrincione C; Leung E; Mayer EL; Naughton M; Toppmeyer D; Carey LA; Perez EA; Hudis C; Winer EP
J Clin Oncol; 2015 Jul; 33(21):2361-9. PubMed ID: 26056183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
